Stock DNA
Pharmaceuticals & Biotechnology
PLN 127 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.04
-85.35%
1.81
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Mar 2025)
Net Profit:
-15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.07%
0%
-14.07%
6 Months
-23.18%
0%
-23.18%
1 Year
-26.69%
0%
-26.69%
2 Years
-60.88%
0%
-60.88%
3 Years
-67.99%
0%
-67.99%
4 Years
-90.01%
0%
-90.01%
5 Years
-66.64%
0%
-66.64%
Mabion SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
73.69%
EBIT Growth (5y)
-0.13%
EBIT to Interest (avg)
-4.49
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.74
Tax Ratio
60.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
31.52%
ROE (avg)
28.14%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.70
EV to EBIT
-2.06
EV to EBITDA
-2.43
EV to Capital Employed
1.79
EV to Sales
11.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-86.62%
ROE (Latest)
-80.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
2.70
4.70
-42.55%
Operating Profit (PBDIT) excl Other Income
-11.80
-16.10
26.71%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
0.70
-100.00%
Consolidate Net Profit
-15.30
-17.90
14.53%
Operating Profit Margin (Excl OI)
-5,215.40%
-3,858.90%
-135.65%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -42.55% vs 840.00% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 14.53% vs -9.82% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
69.00
151.70
-54.52%
Operating Profit (PBDIT) excl Other Income
1.10
74.40
-98.52%
Interest
3.10
1.20
158.33%
Exceptional Items
0.00
-12.20
100.00%
Consolidate Net Profit
-6.30
41.30
-115.25%
Operating Profit Margin (Excl OI)
-109.70%
442.90%
-55.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -54.52% vs -7.50% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -115.25% vs 78.02% in Dec 2023
About Mabion SA 
Mabion SA
Pharmaceuticals & Biotechnology
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Company Coordinates 
Company Details
Ul. gen. Mariana Langiewicza 60 , KONSTANTYNOW LODZKI None : 95-050
Registrar Details






